{"url":"https://newsforagent.com/news/2026-11-11/pfizer-blackstone-obesity-drug-funding","markdown_url":"https://newsforagent.com/news/2026-11-11/pfizer-blackstone-obesity-drug-funding.md","title":"Pfizer Gets Up to $1.5 Billion From Blackstone for Obesity Drug","headline":"Pfizer Secures Up to $1.5 Billion From Blackstone to Fund Monthly Obesity Drug Through 2028","description":"Blackstone will provide up to $1.5 billion through 2028 to fund Pfizer's experimental monthly obesity treatment berobenatide, the company said.","section":"Funding","published_at":"2026-11-11T22:25:35+00:00","modified_at":"2026-11-11T22:25:35+00:00","author":"News Desk","key_takeaways":["Blackstone will provide up to $1.5 billion through 2028 to fund development of Pfizer's experimental monthly obesity treatment.","The agreement is a strategic co-funding arrangement under which Blackstone pays up to $1.5 billion of berobenatide development costs through 2028.","Pfizer acquired Metsera for approximately $10 billion in November 2025, gaining the obesity pipeline that includes berobenatide."],"companies":[{"name":"Pfizer","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00000dw/pfizer","website":"http://www.pfizer.com"},{"name":"Blackstone","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0000ggf/blackstone","website":"http://blackstone.com"}],"source":{"publisher":"MarketScreener","title":"Pfizer secures up to $1.5 billion from Blackstone for obesity drug development","url":"https://www.marketscreener.com/news/pfizer-secures-up-to-1-5-billion-from-blackstone-for-obesity-drug-development-ce785edbd18ef623"},"other_sources":[],"tags":["Funding","Pfizer","Blackstone"],"body_markdown":"Pfizer said Blackstone will provide up to $1.5 billion through 2028 to help fund development of its experimental monthly obesity treatment, according to [MarketScreener](https://www.marketscreener.com/news/pfizer-secures-up-to-1-5-billion-from-blackstone-for-obesity-drug-development-ce785edbd18ef623). The announcement was made on November 11, 2026.\n\n## How the Blackstone Co-Funding Works\n\n[Pfizer](https://akta.pro/company-profiles/00000dw/pfizer) and [Blackstone](https://akta.pro/company-profiles/0000ggf/blackstone) announced a strategic co-funding agreement under which Blackstone will pay up to $1.5 billion of development costs for berobenatide through 2028, Stock Titan reported. The funding is intended to support development of the drug, which Pfizer has described as a monthly obesity treatment.\n\nPfizer plans to launch its GLP-1 drug berobenatide in 2028, aiming to enter a market projected to reach $190 billion by 2035, The Motley Fool reported. The company cites its commercial execution strength, including scaling its COVID vaccine, as a key advantage.\n\nBlackstone separately raised its takeover bid for IDP Education to A$833.7 million, offering A$3 per share at a 36% premium, MarketScreener reported. IDP's board is considering the revised offer, which follows two rejected bids.\n\n## Pfizer's Obesity Pipeline and Deal History\n\nPfizer acquired Metsera for approximately $10 billion in November 2025 following a bidding war with Novo Nordisk, gaining access to an obesity drug pipeline including PF'3944 (berobenatide) and MET-097i for monthly dosing GLP-1 treatments, according to akta.pro [company records](https://akta.pro/company-data). The same records list a $6 billion post-IPO debt round in November 2025 and a $1 billion post-IPO equity round in October 2024 led by Starboard Value.\n\n| Date | Round type | Amount | Lead investor |\n| --- | --- | --- | --- |\n| May 2023 | Post-IPO debt | $31 billion | Not stated |\n| October 2024 | Post-IPO equity | $1 billion | Starboard Value |\n| November 2025 | Post-IPO debt | $6 billion | Not stated |\n\n## Earlier Pfizer Obesity Moves\n\nPfizer is advancing its GLP-1 weight-loss drugs through Phase 3 trials, aiming for a monthly shot option, with 10 late-stage trials, The Motley Fool reported in November 2026. Pfizer CEO outlined a plan to reuse its Viagra-era commercialization playbook for future obesity drugs, citing its $9.7 billion cost-saving program and raised 2026 revenue guidance, Simply Wall St reported.\n\nPfizer and Innovent Biologics partnered on GLP-1 drugs including ecnoglutide, which cleared preliminary review for potential inclusion in China's basic medical insurance drug catalogue for weight management and type II diabetes treatment, according to company records.\n\n## Jefferies Conference Webcast\n\nPfizer will webcast a discussion with CEO Albert Bourla at the Jefferies London Healthcare Conference on November 17, 2026, at 9:00 a.m. GMT, Stock Titan reported. The webcast and replay will be available on Pfizer's investor website within 24 hours and for at least 90 days.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}